Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Agnieszka Rudzińska
Observed names:
A. Rudzińska,
Agnieszka Rudzinska
Institution:
The Maria Sklodowska-Curie National Research Institute of Oncology
Observed institution:
The Maria Sklodowska-Curie National Research Institute of Oncology
ORCID:
0009-0005-7243-4689
Observed ORCID:
0009-0005-7243-4689
OpenAlex ID:
A5083688591
Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis
2023
·
Mirosława Püsküllüoğlu
, Agnieszka Rudzińska
, et al.
·
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
·
20
Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study
2024
·
Miroslawa Püsküllüoğlu
, Małgorzata Pieniążek
, et al.
·
Oncology and Therapy
·
17
PDF
Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience
2024
·
Mirosława Püsküllüoğlu
, Katarzyna Swiderska
, et al.
·
Oncology Letters
·
9
PDF
Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study
2024
·
Mirosława Püsküllüoğlu
, Aleksandra Konieczna
, et al.
·
Acta Oncologica
·
6
PDF
Cisplatin Monotherapy as a Treatment Option for Patients with HER-2 Negative Breast Cancer Experiencing Hepatic Visceral Crisis or Impending Visceral Crisis
2024
·
Mirosława Püsküllüoğlu
, Małgorzata Pieniążek
, et al.
·
Oncology and Therapy
·
6
Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study
2026
·
Justyna Żubrowska
, Małgorzata Pieniążek
, et al.
·
Journal of Neuro-Oncology
·
2
Abstract P4-05-02: Strategies for premedication and neutropenia prophylaxis in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights
2025
·
Miroslawa Puskulluoglu
, Malgorzata Pieniazek
, et al.
·
Clinical Cancer Research
·
2
Unexpected outcomes in the treatment of a patient with metastatic melanoma and immune-related hemophagocytic lymphohistiocytosis
2024
·
Agnieszka Rudzińska
, Miroslawa Püsküllüoğlu
, et al.
·
Polskie Archiwum Medycyny Wewnętrznej
·
2
PDF
Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study
2024
·
Miroslawa Püsküllüoğlu
, Marek Ziobro
, et al.
·
Cancers
·
2
PDF
Non-metastatic primary neuroendocrine neoplasms of the breast: a reference cancer center’s experience of a heterogenous entity
2024
·
Mirosława Püsküllüoğlu
, Aleksandra Grela-Wojewoda
, et al.
·
Frontiers in Endocrinology
·
2
PDF
Validation of the EORTC information (QLQ-INFO25) and satisfaction with care (IN-PATSAT32) modules in the Polish cancer patient population
2025
·
Agnieszka Rudzińska
, Patryk Kukla
, et al.
·
BMC Health Services Research
·
1
PDF
Abstract PS2-04-15: Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from a central European cohort
2026
·
J. Żubrowska
, M. Kubeczko
, et al.
·
Clinical Cancer Research
Abstract PS5-03-08: Effectiveness of sacituzumab govitecan in later-line treatment of mTNBC: real-world evidence from Poland, Czech Republic, and Slovakia according to prior first-line pembrolizumab use
2026
·
J. Żubrowska
, M. Kubeczko
, et al.
·
Clinical Cancer Research
Cisplatin monotherapy as a treatment option for patients with HER-2–negative breast cancer facing hepatic visceral crisis or impending visceral crisis: A single-center cohort study.
2024
·
Miroslawa Puskulluoglu
, Aleksandra Grela-Wojewoda
, et al.
·
Journal of Clinical Oncology
Kardioonkologia w praktyce klinicznej
2023
·
Aleksandra Grela-Wojewoda
, Ewa Konduracka
, et al.
Show more works
View as search
Works count:
15
Citation count:
69
H-index:
5
I10-index:
2
Year
Topic
Type